Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050.
OBJECTIVE
To determine the potency of TKS050, a new epidermal growth factor receptor (EGFR) inhibitor and genistein, a naturally occurring protein tyrosine kinase inhibitor, to inhibit leiomyoma cell proliferation in vitro.


METHODS
Establishment of paired cultures of leiomyoma and normal myometrial samples.


METHODS
University clinical research laboratory.


METHODS
Hysterectomy specimens from premenopausal women affected by uterine leiomyomas.


METHODS
The suppressive effect of TKS050 and genistein on the cells, before and after steroidal hormone treatment, was examined.


METHODS
Cell proliferation, recovery after treatment, cell cycle analysis, and immunochemical analysis of relevant proteins were performed.


RESULTS
TKS050 (2 micromol/L) and genistein (50 micromol/L) completely suppressed leiomyoma cell proliferation, and the cells did not recover after cessation of treatment. TKS050 induced cell cycle arrest and apoptosis in a dose- and time-dependent manner. Cells accumulated in the G(0)/G(1) phase of the cell cycle at the expense of the S and G(2)+M phases. Treatment of cells with TKS050 resulted in a dose-dependent inhibition of EGFR autophosphorylation and of phosphorylated signal transducer and activator of transcription 3 (Stat3). Genistein inhibited the phosphorylated Stat3 but did not affect EGFR autophosphorylation. The inhibitory effects of TKS050 or genistein were unaffected by the presence of physiologic concentrations of estradiol-17beta.


CONCLUSIONS
Leiomyoma cell growth is effectively blocked by TKS050 and genistein. The inhibitory action of newly developed and natural inhibitors derived from diet may be useful as a possible alternative therapy for leiomyomas.
Shushan
Asher
A
Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel. shush@cc.huji.ac.il <shush@cc.huji.ac.il>
Ben-Bassat
Hannah
H
Mishani
Eyal
E
Laufer
Neri
N
Klein
Benjamine Y
BY
Rojansky
Nathan
N
D000970:Antineoplastic Agents / Q000008:administration & dosage; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019833:Genistein / Q000008:administration & dosage*; D006801:Humans; D007889:Leiomyoma / Q000378:metabolism* / Q000473:pathology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured; D014594:Uterine Neoplasms / Q000378:metabolism* / Q000473:pathology*
D000970:Antineoplastic Agents; C516395:N-(4-((3,4-dichloro-6-fluoro-phenyl)amino)quinazoline-6-yl)-2-chloroacetamide; D011799:Quinazolines; D019833:Genistein; D011505:Protein-Tyrosine Kinases